Taiwanese biotech company PharmaEssentia (TPEx: 6446) has entered into a license agreement with the Irish business of WuXi Biologics (2269. HK) for a new immune checkpoint inhibitor.
PharmaEssentia, a company focused on developing new biologics in hematology and oncology, has bought global exclusive rights to research, develop, manufacture and commercialize the myeloid-targeting candidate.
It is a time of considerable change for the Taipei-based firm, as new approvals for its Besremi (ropeginterferon alpha-2b) are secured, starting with the US Food and Drug Administration in 2021.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze